Pharmaceuticals

Polyclonal Antibodies Market 2026 reaching $2.1 billion by 2030

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Polyclonal Antibodies Market During The Forecast Period 2026–2030?

The polyclonal antibodies market size has shown significant growth in recent years. It is anticipated to increase from $1.48 billion in 2025 to $1.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. This historical growth can be attributed to several factors including a surging demand for immunoassays, the increased utilization of polyclonal antibodies in research, the expansion of the biotechnology sector, a rise in academic research activities, and the availability of animal models for antibody production.

The polyclonal antibodies market is poised for substantial expansion over the next few years. It is projected to achieve a size of $2.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This anticipated growth throughout the forecast period stems from factors such as the proliferation of precision medicine initiatives, the rising adoption of therapeutic antibody applications, advancements in antibody production technologies, increased investments in diagnostics research, and enhanced collaborations between pharmaceutical companies and research institutions. Prominent trends expected during this period involve innovative polyclonal antibody production techniques, the provision of custom antibody development services, their expanding utility in diagnostic applications, growth within therapeutic research applications, and an increase in academic and pharmaceutical research partnerships.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10790&type=smp

What Drivers Are Expected To Influence The Polyclonal Antibodies Market During The Forecast Period?

The growing occurrence of cancer is anticipated to boost the expansion of the polyclonal antibodies market in the future. Cancer, defined by the unregulated multiplication and growth of cells that cause tissue harm and potential spread, continues to be a primary global contributor to illness and death. The surge in cancer incidents is fueled by elements like an aging global population, evolving lifestyles, and exposure to environmental factors. In cancer research and treatment, polyclonal antibodies are extensively utilized for identifying biomarkers, immunohistochemistry, targeted therapy, and immunotherapy, thereby enhancing diagnostic accuracy, therapeutic effectiveness, and patient results. A concrete example highlights this trend: in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, predicted that by 2050, more than 35 million new cancer cases would arise, marking a 77% increase from the approximate 20 million cases recorded in 2022. Consequently, the expanding prevalence of cancer is propelling the growth of the polyclonal antibodies market.

What Market Segments Are Evaluated Within The Polyclonal Antibodies Market?

The polyclonal antibodies market covered in this report is segmented –

1) By Product Type: Primary Antibody, Secondary Antibody

2) By Source: Rabbits, Goats, Sheep, Other Sources

3) By Application: Research, Diagnostics, Therapy

4) By End-User: Academic and Research Center , Pharmaceutical and Biotechnology Companies, Diagnostic Centers , Hospitals

Subsegments:

1) By Primary Antibody: Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), Immunoglobulin E (IgE)

2) By Secondary Antibody: Anti-Mouse IgG, Anti-Rabbit IgG, Anti-Goat IgG, Other Secondary Antibodies

What Industry Trends Are Redefining The Polyclonal Antibodies Market?

Leading companies in the polyclonal antibodies market are concentrating on developing advanced solutions, such as hyperimmune antibody therapies, to enhance patient outcomes, reduce severe complications, and improve immune responses. Hyperimmune antibody therapies involve the use of polyclonal antibodies derived from plasma donors with high levels of neutralizing antibodies, providing targeted immune protection against viral infections. For instance, in April 2023, SAB Biotherapeutics, a US-based biotechnology company, announced positive Phase 3 trial results for SAB-185, its fully human polyclonal antibody therapy, in patients at high risk for severe COVID-19 complications. Designed to neutralize SARS-CoV-2 effectively, SAB-185 demonstrated safety and efficacy, highlighting the potential of polyclonal antibody therapies to improve treatment outcomes in vulnerable patient populations.

Who Are The Top Market Participants Influencing The Polyclonal Antibodies Market?

Major companies operating in the polyclonal antibodies market are Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., ImmonoPresice Antibodies Ltd, Fujirebio, Omega BioTek Inc., Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell

Read the full polyclonal antibodies market report here:

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Which Region Is Forecast To Lead The Polyclonal Antibodies Market In Terms Of Market Size?

North America was the largest region in the polyclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Polyclonal Antibodies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10790&type=smp

Browse Through More Reports Similar to the Global Polyclonal Antibodies Market 2026, By The Business Research Company

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Monoclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795